Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Gains from Sales and Divestitures (2016 - 2025)

Historic Gains from Sales and Divestitures for Voyager Therapeutics (VYGR) over the last 10 years, with Q3 2025 value amounting to $568331.0.

  • Voyager Therapeutics' Gains from Sales and Divestitures rose 3424.23% to $568331.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $568331.0, marking a year-over-year increase of 3424.23%. This contributed to the annual value of $515303.0 for FY2024, which is 305.84% down from last year.
  • Voyager Therapeutics' Gains from Sales and Divestitures amounted to $568331.0 in Q3 2025, which was up 3424.23% from $550084.0 recorded in Q2 2025.
  • Over the past 5 years, Voyager Therapeutics' Gains from Sales and Divestitures peaked at $568331.0 during Q3 2025, and registered a low of $184217.0 during Q1 2021.
  • In the last 5 years, Voyager Therapeutics' Gains from Sales and Divestitures had a median value of $419999.0 in 2022 and averaged $402480.6.
  • In the last 5 years, Voyager Therapeutics' Gains from Sales and Divestitures soared by 12970.93% in 2021 and then plummeted by 1332.66% in 2024.
  • Voyager Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $326943.0 in 2021, then soared by 33.54% to $436611.0 in 2022, then grew by 21.75% to $531560.0 in 2023, then dropped by 3.06% to $515303.0 in 2024, then rose by 10.29% to $568331.0 in 2025.
  • Its Gains from Sales and Divestitures stands at $568331.0 for Q3 2025, versus $550084.0 for Q2 2025 and $450556.0 for Q1 2025.